Torex Gold Outlines Multi-Year Exploration StrategyPipeline of high-quality targets systematically prioritized to unlock the full potential of MorelosJune 10, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - June 10, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) is pleased to provide detail on a multi-year exploration strategy for its highly prospective Morelos Proper ...

 New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughputPLEASANTON, Calif., May 29, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and s ...

Torex Gold Releases 2023 Responsible Gold Mining ReportReport shines a spotlight on continued excellence in ESG performance and disclosureMay 21, 2024 6:00 PM EDT | Source: Torex Gold Resources Inc.(All amounts expressed in U.S. dollars unless otherwise stated)Toronto, Ontario--(Newsfile Corp. - May 21, 2024) - Torex Gold Resources Inc. (the "Company" or "Torex") (TSX: TXG) today released its 2023 Responsible Gold Mining Report (the "Report") titled At the Heart of Who we Are, the Company's ni ...

Have you evaluated the performance of 10x Genomics' (TXG) international operations for the quarter ending March 2024? Given the extensive global presence of this life science technology company, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become ...

财务数据和关键指标变化 - 总收入为1.41亿美元,同比增长5% [8] - 消耗品收入为1.103亿美元,同比下降2% [34] - 空间消耗品收入为2,640万美元,同比增长134% [34] - Chromium消耗品收入为8,390万美元,同比下降17% [35][36] - 仪器收入为2,550万美元,同比增长33% [38] - 空间仪器收入为1,760万美元,同比增长133% [38] - Chromium仪器收入为790万美元,同比下降32% [38] - 服务收入为520万美元,同比增长91% [39] 各条业务线数据和关键指标变化 - 空间业务保持强劲增长,主要由Xenium和Visium HD带动 [8][11][12] - Chromium业务受到GEM-X产品过渡和客户对空间业务关注的影响 [35][36][37][51] - 公司正在采取措施提高Chromium业务的重点和执行力 [79][80][81][102] 各个市场数据和关键指标变化 - 美洲地区收入增长1%至7,960万美元 [40] - EMEA地区收入增长22%至3,470万美元 [40] - APAC地区收入下降2%至2,670万美元 [40] - 中国市场收入下降16%,公司正在采取措施应对分销商库存积压问题 [93][94][95] 公司战略和发展方向及行业竞争 - 公司推出多款新产品,包括Visium HD、GEM-X等,持续保持技术领先地位 [8][11][18][19] - 公司看好单细胞和空间生物学的长期发展前景,将继续投资3大平台 [9][24][30][102] - 面临新竞争对手的挑战,但公司产品性能和客户支持优势仍然明显 [97][98][99][102] 管理层对经营环境和未来前景的评论 - 公司看好单细胞和空间生物学的长期发展前景,但短期内受到一些因素影响 [9][22][30][45][46] - 公司将继续保持长期战略导向,保持创新投入,满足客户需求 [25][29][30][102] - 公司对Visium HD和GEM-X产品的市场反响和未来发展前景持乐观态度 [11][12][19][20][21] 问答环节重要的提问和回答 问题1 **Mason Carrico 提问** 询问Visium HD和GEM-X的采用情况和客户反馈 [50] **Justin McAnear 和 Serge Saxonov 回答** - Visium HD约一半客户采用,带动CytAssist仪器需求 [51][52] - GEM-X在Q2已占Chromium消耗品约1/3,客户反馈积极 [51][52][53][54] 问题2 **Patrick Donnelly 提问** 询问Chromium业务的增长前景 [57] **Justin McAnear 回答** - GEM-X过渡、空间业务关注和宏观因素共同影响Chromium业务 [58][59][60] - 预计Q2Chromium业务仍受影响,全年公司维持此前收入指引 [58][59][60] 问题3 **Dan Arias 提问** 询问GEM-X过渡的时间线及Chromium全年增长预期 [64] **Serge Saxonov 和 Justin McAnear 回答** - GEM-X过渡预计会相对较快,客户反馈积极 [65][66] - 受GEM-X过渡和其他因素影响,Chromium全年增长目标将更加具有挑战性 [67]

10x Genomics (TXG) reported $141.01 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5%. EPS of -$0.50 for the same period compares to -$0.44 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $142.04 million, representing a surprise of -0.73%. The company delivered an EPS surprise of -8.70%, with the consensus EPS estimate being -$0.46.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

Exhibit 99.1 10x Genomics Reports First Quarter 2024 Financial Results PLEASANTON, Calif. April 30, 2024 – 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the first quarter ended March 31, 2024. Recent Highlights • Revenue was $141.0 million for the first quarter, a 5% increase over the corresponding period of 2023, driven by Spatial revenue. • Shipped Visium HD Spatial Gene Expression, enabling whole transcriptome spatial discovery at sing ...

10x Genomics盈利情况 - 10x Genomics最近被升级为Zacks Rank 2 (Buy)，这是因为其盈利预期呈上升趋势[1] - 10x Genomics的Zacks评级升级实际上是对其盈利前景的积极评价，可能对其股价产生有利影响[4] - 10x Genomics的盈利预期逐渐上升，过去三个月，公司的Zacks共识估计增长了5%[10] - 10x Genomics被升级为Zacks Rank 2，使其在Zacks覆盖的股票中处于前20%，暗示股价可能在短期内上涨[13]

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applicatio ...